• 1
    Rustgl VK. Epidemiology of hepatocellular carcinoma. Gastroenterol Clin North Am. 1987; 16: 545551.
  • 2
    Chan D, Sell S. Tumor markers. In: BurtisCA, AshwoodA, editors. Tietz textbook of clinical chemistry, 3rd ed. Philadelphia: Saunders, 1999: 722749.
  • 3
    Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001; 34: 570575.
  • 4
    Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002; 31: 339346.
  • 5
    Ishii M, Gama H, Chida N, et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol. 2000; 95: 10361040.
  • 6
    Ono M, Ohta H, Ohhira M, Sekiya C, Namiki M. Measurement of immunoreactive prothrombin precursor and vitamin-K dependent gamma-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis. Tumor Biol. 1990; 11: 319326.
  • 7
    Marrero JA, Su GL, Wei W, et al. Des-gamma carboxythrombin can differentiate hepatocellular carcinoma from non malignant chronic liver disease in American patients. Hepatology. 2003; 37: 11141121.
  • 8
    Grazi GL, Mazziotti A, Legnani C, et al. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxyprothrombin. Liver Transplant Surg. 1995; 4: 249255.
  • 9
    Hsu HC, Chen W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997; 57: 51795184.
  • 10
    Capurro M, Wanless IR, Sherman M., et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003; 125: 8997.
  • 11
    Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Comm. 2003; 306: 1625.
  • 12
    Trojan J, Raedle J, Zeuzem S. Serum tests for diagnosis and follow-up of hepatocellular carcinoma after treatment. Digestion. 1998; 59: 7274.
  • 13
    Pontisso P, Calabrese F, Benvegnù L, et al. Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. Br J Cancer. 2004; 90: 833837.
  • 14
    Kato H. Expression and function of squamous cell carcinoma antigen. Anticancer Res. 1996; 16: 21492154.
  • 15
    Suminami Y, Shigeki N, Murakami A, et al. Suppression of a squamous cell carcinoma (SCC)-related serpin, SCC Antigen, inhibits tumor growth with increased intratumoral infiltration of killer cells. Cancer Res. 2001; 61: 176180.
  • 16
    Beneduce L, Castaldi F, Marino M, et al. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. Int J Biol Markers. 2004; 19: 155159.
  • 17
    Guido M, Pontisso P, Cillo U, et al. Expression of squamous cell carcinoma antigen in hepatocellular carcinoma and its precursors [abstract]. J Hepatol. 2004; 40(Suppl 1): 78.
  • 18
    Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother. 2004; 58: 2438.
  • 19
    Boon T, Van den Eynde B. Tumour immunology. Curr Opin Immunol. 2003; 15: 129130.
  • 20
    Fuchs C, Krapf F, Kern P, Hoferichter S, Jager W, Kalden JR. CEA-containing immune complexes in sera of patients with colorectal and breast cancer—analysis of complexed immunoglobulin classes. Cancer Immunol Immunother. 1988; 26: 180184.
  • 21
    Habal N, Gupta RK, Bilchick AJ, Johnson T, Morton DL. TA90-IC, a new marker for advanced colon cancer. Ann Surg Oncol. 2000; 7: 352356.
  • 22
    Croce MV, Isla-Larrain MT, Demichelis SO, Gori JR, Price MR, Segal-Eiras A. Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat. 2003; 81: 195207.
  • 23
    Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for loco-regional breast cancer. Lancet. 1995; 345: 621622.